基金参与调研的公司中，按所属板块统计，深市主板公司有1家，创业板公司有5家，科创板公司有1 家，北交所公司有1家。 从基金调研公司的A股总市值统计，总市值不足100亿元的有7家，分别是迦南科技、超达装备、博盈特 焊等。 昨日基金共对8家公司进行调研，扎堆调研博盈特焊、嘉益股份、英诺激光等。 证券时报·数据宝统计，11月10日共13家公司被机构调研，按调研机构类型看，基金参与8家公司的调研 活动。博盈特焊最受关注，参与调研的基金达17家；嘉益股份、英诺激光等分别获9家、5家基金集体调 研。 11月10日基金调研公司一览 | 代码 | 简称 | 基金家数 | 最新收盘价（元） | 近5日涨跌幅（%） | 行业 | | --- | --- | --- | --- | --- | --- | | 301468 | 博盈特焊 | 17 | 40.76 | -4.03 | 机械设备 | | 301004 | 嘉益股份 | 9 | 54.86 | -3.94 | 轻工制造 | | 301021 | 英诺激光 | 5 | 43.98 | 5.29 | 机械设备 | | 920509 | 同惠电子 | 3 | 37.46 | ...

证券日报网讯普门科技11月10日在互动平台回答投资者提问时表示，经过多年的发展和积累，普门科技 在研发、市场营销、供应链等方面逐步建立起较强的核心能力，初步具备了高效管理和驾驭多产品线、 多市场的能力。 ...

[Table_Reportdate] 2025年11月05日 [证券分析师： Table_Authors] 赖菲虹 S0630525050001 lfhong@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20251105 重点推荐 财经要闻 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 晨 会 纪 要 [table_summary] ➢ 1.北方华创（002371）：2025Q3业绩高速增长，平台化布局成效卓著——公司简评报告 ➢ 2.预定利率研究值小幅下调至1.90%，预计短期上限水平保持稳定——保险业态观察（十） ➢ 3.众生药业（002317）：业绩稳健增长，研发进展顺利——公司简评报告 ➢ 4.普门科技（688389）：国际业务增长迅速，静待行业政策影响出清——公司简评报告 ➢ 5.常熟银行（601128）：息差压力缓解，非息收入增长强劲——公司简评报告 ➢ ...

2、根据《公司2023年股票期权激励计划（草案）》的相关规定，截至2025年9 月11日，鉴于2023年股票期权激励计划授予激励对象中有6名激励对象已离职，以及 公司2023年股票期权激励计划第一个行权期可行权期限已经届满，154名激励对象持 有的股票期权合计1,937,998份（其中包括6名离职激励对象未行权的股票期权120,000 份）在可行权期限内未行权，拟由公司进行注销。 证券代码：688389 证券简称：普门科技 公告编号：2025-076 深圳普门科技股份有限公司 关于2021年股票期权激励计划首次授予部分股票期权、 2023年股票期权激励计划部分股票期权注销完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于2025年10月27日召开了第 三届董事会第十九次会议和第三届监事会第十八次会议，审议通过了《关于注销 2021年股票期权激励计划首次授予部分股票期权的议案》《关于注销2023年股票期 权激励计划部分股票期权的议案》。前述董事会、监事会审议的注销事项具 ...

Core Viewpoint - Pumen Technology (688389) has experienced a decline in stock price and financial performance, with significant drops in revenue and net profit, while international business shows growth potential in the medical device sector [1][3][4]. Stock Performance - As of October 31, 2025, Pumen Technology's stock closed at 13.81 yuan, down 0.14% from the previous week, with a market cap of 5.917 billion yuan, ranking 61st in the medical device sector [1]. Shareholder Changes - As of September 30, 2025, the number of shareholders decreased to 11,900, a reduction of 500 or 4.05%, while the average shareholding increased to 36,100 shares, with an average market value of 499,300 yuan [2]. Financial Performance - For Q3 2025, Pumen Technology reported a main revenue of 763 million yuan, a year-on-year decrease of 10.96%, and a net profit of 163 million yuan, down 36.66%. The gross profit margin was 63.29% [3]. Research and Development - In the first three quarters of 2025, R&D expenses reached 170 million yuan, accounting for 22.23% of revenue, an increase of 4.10 percentage points year-on-year. The gross margin decreased by 3.82 percentage points [4][5]. International Business Growth - International business revenue for the first three quarters was 294 million yuan, representing 39% of total revenue and a year-on-year increase of 16.41%. The international in vitro diagnostics revenue was 270 million yuan, up 14% [4]. Product Development - The company has made significant advancements in product offerings, including the eCL8600 and eCL8800 series, which have met market expectations since their launch in June. The semiconductor laser hair removal device has received FDA certification, facilitating entry into the North American market [4][5]. Consumer Health Business - The consumer health business, while currently a small revenue contributor, has shown significant growth, focusing on home medical aesthetics and rehabilitation products, with positive market feedback [5].

Core Viewpoint - Pumen Technology, a leading medical device company in China, focuses on in vitro diagnostics and rehabilitation products, leveraging technological innovation and a full industry chain advantage to establish its position in the market [1] Group 1: Business Performance - For Q3 2025, Pumen Technology reported revenue of 763 million yuan, ranking 13th among 39 companies in the industry, with the top company, New Industries, achieving 3.428 billion yuan [2] - The net profit for the same period was 159 million yuan, placing the company 8th in the industry, while the leading company, Ji'an Medical, reported a net profit of 1.588 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Pumen Technology's debt-to-asset ratio was 20.77%, lower than the previous year's 30.95% but still above the industry average of 18.29% [3] - The gross profit margin for the same period was 63.29%, down from 69.89% year-on-year, yet higher than the industry average of 56.20% [3] Group 3: Executive Compensation - Chairman Liu Xiancheng's salary increased to 2.0519 million yuan in 2024, up from 977,600 yuan in 2023, reflecting a rise of 1.0743 million yuan [4] - General Manager Hu Minglong's salary rose to 1.2455 million yuan in 2024 from 1.0897 million yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.05% to 11,900, while the average number of circulating A-shares held per shareholder increased by 4.22% to 36,100 [5] - The top ten circulating shareholders include the "Zhaoshang Core Competitiveness Mixed A" fund, holding 6.2561 million shares, unchanged from the previous period [5] Group 5: Market Outlook - According to Dongfang Securities, Pumen Technology's mid-year report for 2025 indicated a year-on-year decline in revenue and net profit, with domestic business under short-term pressure but international business showing steady growth [5] - Huachuang Securities noted that while the company's mid-year performance declined, Q2 2025 saw a return to growth, with international business performing well despite short-term challenges in the IVD sector [5]

Core Viewpoint - The company, Pumen Technology, reported a decline in revenue and net profit for the first three quarters of 2025, with a focus on improving its product offerings and market competitiveness in the IVD and treatment sectors [2][12]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 763 million yuan, a year-on-year decrease of 10.96% - The net profit attributable to the parent company was 163 million yuan, down 36.66% year-on-year - The net profit after deducting non-recurring gains and losses was 153 million yuan, a decline of 37.18% year-on-year - In Q3 2025, the company reported revenue of 256 million yuan, a decrease of 4.06% year-on-year, and a net profit of 41.46 million yuan, down 51.52% year-on-year [2][12]. R&D and Product Development - The company invested 170 million yuan in R&D for the first three quarters, accounting for 22.23% of revenue, with a year-on-year increase of 9.20% in R&D expenses [2][8]. - The company has established two business units focusing on IVD and treatment & rehabilitation, with ongoing efforts in new product development and upgrades to existing products [8][9]. Market and Product Strategy - The domestic IVD business faced challenges due to industry policies, but the company is seeing growth in its glycated hemoglobin testing products, particularly the H100Plus model, which has been installed in several top-tier hospitals [3][4]. - The company has successfully installed its eCL9000 series and LifoLas systems in multiple hospitals, establishing a comprehensive product matrix to meet various medical institution needs [4]. - International business revenue reached 294 million yuan, accounting for 39% of total revenue, with a year-on-year growth of 16.41% [6]. Future Outlook - The company plans to continue its R&D investments and product international registrations, aiming to enhance product competitiveness and market presence [9]. - Measures to improve gross margins include technological innovation, self-research of key raw materials, and cost control strategies [10].

Core Insights - The Social Security Fund has disclosed its stock holdings as of the end of the third quarter, appearing in the top ten shareholders of 49 stocks on the Sci-Tech Innovation Board, with a total holding of 203 million shares valued at 13.02 billion yuan [1][2]. Holdings Overview - The Social Security Fund initiated positions in 19 new stocks and increased holdings in 11 stocks, while reducing holdings in 11 stocks, with 8 stocks remaining unchanged [1]. - Among the newly added stocks, Pumen Technology, Hangya Technology, and Sanyou Medical had the largest shareholdings [1]. - The stocks with the highest proportion of holdings by the Social Security Fund include Kaili New Materials at 5.80% and Haitai New Light at 4.20% [2]. Stock Performance - The average performance of the Sci-Tech Innovation Board stocks held by the Social Security Fund has seen a decline of 2.05% since October [3]. - The best-performing stock is Western Superconducting, which has increased by 34.00%, while the worst performer is Jiahe Meikang, which has decreased by 20.25% [3]. Financial Performance - Among the stocks held by the Social Security Fund, 30 companies reported year-on-year net profit growth in the first three quarters, with Rongzhi Rixin showing the highest increase of 889.54% [2]. - Other notable companies with significant net profit growth include Sanyou Medical and Shenkong Co., with increases of 623.19% and 158.93%, respectively [2]. Industry Distribution - The holdings of the Social Security Fund are primarily concentrated in the electronics, pharmaceutical and biological, and machinery equipment sectors, with 15, 7, and 7 stocks in these categories, respectively [2].

Core Insights - Pumen Technology (688389.SH) reported its Q3 2025 results, revealing that as of October 28, 2025, seven institutional investors held a total of 51.5351 million A-shares, representing 12.03% of the company's total equity [1] - The institutional holding percentage increased by 1.62 percentage points compared to the previous quarter [1] Institutional Holdings - The institutional investors include Xiamen Hanyu Investment Consulting Partnership, National Social Security Fund 604 Portfolio, Xiamen Qiaochuan Investment Partnership, Ping An Bank's mixed securities investment fund, Xiamen Purong Investment Partnership, and others [1] - One new public fund was disclosed during this period, namely the Chuangjin Hexin Qifu Preferred Stock Initiation A [1] - A total of 128 public funds were not disclosed in this period, including several ETFs and mixed funds [1] Social Security Fund - One new social security fund disclosed its holdings in Pumen Technology, specifically the National Social Security Fund 604 Portfolio [1]

Core Insights - The social security fund has disclosed its stock holdings for the third quarter, appearing in the top ten circulating shareholders of 29 stocks, with 13 new entries and 6 increases in holdings [1][2] Group 1: Stock Holdings Overview - The social security fund holds a total of 141 million shares in the listed stocks, with a market value of approximately 9.284 billion yuan [1] - The most significant new entries include Pumen Technology, Sanyou Medical, and Huazhu Gaoke, with notable holdings [1] - The stock with the highest number of social security fund holders is Kaili New Materials, with three funds listed among the top ten shareholders, holding a total of 7.5825 million shares, accounting for 5.80% of circulating shares [1][2] Group 2: Shareholding Proportions and Performance - Kaili New Materials has the highest shareholding ratio at 5.80%, followed by Haitai New Light at 4.20%, and other notable companies include Aohua Endoscopy and Nanwei Medical [2] - The fund holds over 10 million shares in two companies, with Transsion Holdings having the largest holding of 32.7184 million shares [2] - The top three stocks by market value held by the fund are Transsion Holdings (3.082 billion yuan), Anji Technology (775 million yuan), and Nanwei Medical (629 million yuan) [2] Group 3: Financial Performance - Among the stocks held by the social security fund, 19 companies reported year-on-year net profit growth in the first three quarters, with Sanyou Medical showing the highest increase of 623.19% [2] - Other companies with significant net profit growth include Shengong Co. and New Xiangwei, with increases of 158.93% and 138.88%, respectively [2] Group 4: Market Performance - The average decline of the stocks held by the social security fund since October is 3.93%, with Kaili New Materials being the best performer with a rise of 6.11% [3] - The largest decline was seen in Lexin Technology, which dropped by 19.81% [3]